C12N 5/0686
Kidney cells
Official title: {Kidney cells}
C12N5/0686 (Kidney cells) appears on 238 US grants and 517 published applications in this corpus.
Search patents in C12N- Granted patents
- 238
- Published applications
- 517
- Assignees
- 327
- Inventors
- 1,200
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 1 |
| 2002 | 3 | 1 |
| 2003 | 1 | 5 |
| 2004 | 4 | 7 |
| 2005 | 2 | 8 |
| 2006 | 2 | 6 |
| 2007 | 4 | 8 |
| 2008 | 1 | 11 |
| 2009 | 1 | 5 |
| 2010 | 2 | 11 |
| 2011 | 4 | 13 |
| 2012 | 6 | 7 |
| 2013 | 10 | 17 |
| 2014 | 6 | 10 |
| 2015 | 9 | 20 |
| 2016 | 7 | 15 |
| 2017 | 12 | 8 |
| 2018 | 9 | 25 |
| 2019 | 12 | 27 |
| 2020 | 17 | 35 |
| 2021 | 15 | 27 |
| 2022 | 12 | 36 |
| 2023 | 20 | 34 |
| 2024 | 19 | 66 |
| 2025 | 22 | 65 |
| 2026 | 21 | 49 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fas-associated factor 1 (FAF1)-loaded exosomes and use thereof as anti-cancer agent29 Sep 2026US 12,746,271 B2Kainos Medicine, Inc.
- Composition of shelf-stable plasmid dna/polyethyleneimine (pei) particles with defined sizes for viral vector production and method for preparation of the same25 Aug 2026US 12,716,073 B2The Johns Hopkins University
- Methods for reducing elevated glucose levels11 Aug 2026US 12,703,856 B2SDF BioPharma Inc.
- VSV rescue7 Jul 2026US 12,674,143 B2Boehringer Ingelheim International GmbH
- MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production30 Jun 2026US 12,667,612 B2Fujifilm Biosciences Inc.
- Compositions and methods for controlling patterning of human kidney organoid nephrons1 Oct 2026US 2026/0297532 A1University of Southern California
- Microfluidic devices and methods of designing and using microfluidic devices24 Sep 2026US 2026/0286265 A1Javelin Biotech, Inc.
- Suspension mode seed train development for adherent cells10 Sep 2026US 2026/0265701 A1Sarepta Therapeutics, Inc.
- Il2 muteins and uses thereof3 Sep 2026US 2026/0258107 A1Elpiscience Biopharma, Ltd.
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
Most cited
By later US patents
- Culturing different cell populations on a decellularized natural biostructure for organ reconstruction150US 6,479,064 B1Children's Medical Center Corporation · 2002
- Nucleotide-specific recognition sequences for designer TAL effectors84US 8,450,107 B1Massachusetts Institute of Technology · 2013
- Nucleotide-specific recognition sequences for designer TAL effectors84US 8,614,092 B2Massachusetts Institute of Technology · 2013
- Nucleotide-specific recognition sequences for designer TAL effectors76US 8,507,272 B2Massachusetts Institute of Technology · 2013
- Nucleotide-specific recognition sequences for designer TAL effectors67US 8,481,309 B2Massachusetts Institute of Technology · 2013